FDA approves juxtapid for rare cholesterol disorder

FDA approves juxtapid for rare cholesterol disorder
The U.S. Food and Drug Administration has approved the orphan drug Juxtapid (lomitapide) for patients with homozygous familial hypercholesterolemia, for use in combination with a low-fat diet and other lipid lowering treatments, according to a Dec. 26 press release.

(HealthDay)—The U.S. Food and Drug Administration has approved the orphan drug Juxtapid (lomitapide) for patients with homozygous familial hypercholesterolemia (HoFH), for use in combination with a low-fat diet and other lipid lowering treatments, according to a Dec. 26 press release.

Juxtapid, an orphan drug marketed by Cambridge, Mass.-based Aegerion Pharmaceuticals Inc., was evaluated in a trial including 29 patients with HoFH, an inherited disorder of high low-density lipoprotein (LDL) cholesterol. For those who tolerated the drug, levels of LDL cholesterol decreased by approximately one-half during the first 26 weeks.

Juxtapid, a capsule taken once a day, without food, at least two hours after the evening meal, carries a boxed warning regarding a serious risk of . Juxtapid also decreases the absorption of fat-soluble nutrients and, consequently, patients should take supplements that contain fat-soluble nutrients and essential fatty acids while taking Juxtapid. Juxtapid also interacts with several other medications.

"Juxtapid, in addition to diet changes and other cholesterol-lowering treatments, is a new option for those suffering with HoFH and the serious resulting from this condition," Eric Colman, M.D., deputy director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research, said in a statement.

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

Monthly shot lowers cholesterol 66 percent: study

Mar 26, 2012

A monthly injection of an experimental drug made by the US biotech firm Amgen reduced patients' cholesterol by up to 66 percent, according to a small study described at a US cardiology conference.

Recommended for you

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.